971__981__

Psychiatr. Pol. 2018; 52(6): 971–981

 

Błażej Misiak, Przemysław Bieńkowski, Jerzy Samochowiec
 

FREE POLISH FULLTEXT:
 

FREE ENGLISH FULLTEXT:

Summary
Although the development of second-generation antipsychotics was a cornerstone in the treatment of schizophrenia, several unmet treatment needs in the field still exist. It is particularly important to note that available antipsychotics have limited efficacy in the treatment of negative symptoms and cognitive impairment. At this point, it should be noted that primary negative symptoms, i.e., those that are not due to depression, extrapyramidal symptoms or psychotic withdrawal, might affect even one-fourth of patients with schizophrenia and are associated with poor clinical and functional outcomes. Cariprazine, is an emerging antipsychotic drug, D3/D2 receptor partial agonist, with affinity to several serotonin receptors. In this article, we provide an overview of pharmacokinetic and pharmacodynamic properties of cariprazine, showing its unique receptor profile. Next, we discuss results of double-blind, placebo-controlled, randomized clinical trials and post hoc analyses of cariprazine that have been published to date. These studies have provided evidence for efficacy of cariprazine in the treatment of schizophrenia exacerbations compared to placebo, with safety and good tolerability. In addition, one clinical trial published to date revealed superior efficacy of cariprazine compared to risperidone in the treatment of predominant negative symptoms that had been also associated with concomitant improvement of functional performance. Overall, current evidence in the field supports the use of cariprazine in exacerbation of schizophrenia and suggests promising efficacy in the treatment of predominant negative symptoms.




ISSN 0033-2674 (PRINT)

ISSN 2391-5854 (ONLINE)


Psychiatria Polska
is an Open Access journal:
Creative Commons: CC-BY
SHERPA RoMEO:
Blue


Zadanie finansowane
w ramach umowy
nr 739/P-DUN/2018
ze środków MNiSW
przeznaczonych
na działalność
upowszechniającą naukę


KRW PTP dziękuje 
firmie PPL – Koral – J.Koral sp.j.
za wsparcie finansowe 
udzielone w 2020 roku




Inne strony PTP:
Other PTP websites:

www.psychiatria.org.pl
www.psychiatriapsychoterapia.pl

www.archivespp.pl
www.psychoterapiaptp.pl

Psychiatria Polska
INDEXED IN:
Thomson Reuters Master List
Science Citation Index Expanded
Journal Citation Reports
(Impact Factor 1,311)

Medline/Index Medicus
PubMed/LinkOut
MNiSW (40 pkt)
Scopus/SCImago
(SJR 0,345; H index 18 pkt)
EMBASE/Excerpta Medica
PsycINFO, EBSCO,
Index Copernicus (159 pkt)
Erih Plus, Cochrane Library
CrossRef/DOI

We recommend:

Pharmacological Reports

 


KONTAKT Z REDAKCJĄ - wyłącznie e-mail: redakcja@psychiatriapolska.pl 

Biuro KRW PTP - prenumeraty, faktury:  518-330-994 lub biuro@krwptp.pl 
krwptp.pl